TERT and neoplasm: Similar to our findings, few studies have used ddPCR to identify the prevalence of TERT promoter mutation in blood and urinary cell-free tumor DNA and FFPE specimens to monitor melanoma (32–34), urothelial cancer (35), glioma (36), and thyroid (37).